Intensity Therapeutics, Inc. (INTS)
NASDAQ:INTS
Top Page
Intensity Therapeutics, Inc.
(NASDAQ:INTS)
Select Model
Select Model
Rating:43Neutral
Price Target:
$6.00
▲(2.04% Upside)
Action:ReiteratedDate:03/28/26
The score is primarily weighed down by weak financial performance (no revenue, ongoing losses, and sustained cash burn) and bearish technicals (below major moving averages with negative MACD). Corporate events slightly support the score via regained Nasdaq compliance, but the reverse split and loss-making valuation profile keep overall risk elevated.
Positive Factors
Strong Patent Protection
A broad patent estate across 41 countries covering the DfuseRx platform and INT230-6 creates a durable IP barrier to entry, supports exclusive commercial rights, and strengthens leverage in partnering or licensing talks—structural advantages that persist across clinical and regulatory timelines.
Negative Factors
No Revenue / Persistent Losses
As a pre-commercial biotech, the company has generated no product revenue for years and records persistent net losses. This structural lack of operating income extends reliance on external funding until clinical success and commercialization, amplifying long-term execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Patent Protection
A broad patent estate across 41 countries covering the DfuseRx platform and INT230-6 creates a durable IP barrier to entry, supports exclusive commercial rights, and strengthens leverage in partnering or licensing talks—structural advantages that persist across clinical and regulatory timelines.
Read all positive factors
Intensity Therapeutics, Inc. (INTS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$14.94M
Dividend YieldN/A
Average Volume (3M)5.11M
Price to Earnings (P/E)―
Beta (1Y)0.63
Revenue GrowthN/A
EPS Growth46.41%
CountryUS
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)1.69
Shares Outstanding2,540,518
10 Day Avg. Volume8,790,984
30 Day Avg. Volume5,112,980
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)11.72
Price to Sales (P/S)0.00
P/FCF Ratio-15.07
Enterprise Value/Market Cap-0.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit83.16
Enterprise Value/Ebitda0.12
Forecast
1Y Price Target
$25.00Price Target Upside325.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-4.63
Revenue Forecast (FY)N/A
Intensity Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinica...
How the Company Makes Money
As a clinical-stage biotechnology company, Intensity Therapeutics has not disclosed a recurring commercial product revenue stream. Its funding has primarily come from capital-raising activities typical for pre-commercial biopharma companies, inclu...
Intensity Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -26.00K | 0.00 | -147.00K | 0.00 | 0.00 |
| EBITDA | -11.97M | -16.27M | -10.09M | -7.50M | -7.88M |
| Net Income | -11.61M | -16.27M | -10.54M | -7.58M | -7.90M |
Balance Sheet | |||||
| Total Assets | 14.10M | 4.78M | 17.30M | 1.76M | 5.22M |
| Cash, Cash Equivalents and Short-Term Investments | 11.92M | 2.59M | 14.78M | 1.31M | 4.54M |
| Total Debt | 110.00K | 138.00K | 158.00K | 4.49M | 2.34M |
| Total Liabilities | 2.23M | 1.86M | 4.13M | 16.86M | 13.90M |
| Stockholders Equity | 11.88M | 2.92M | 13.16M | -15.10M | -8.68M |
Cash Flow | |||||
| Free Cash Flow | -9.23M | -15.22M | -7.21M | -5.48M | -6.83M |
| Operating Cash Flow | -9.23M | -15.22M | -7.21M | -5.48M | -6.83M |
| Investing Cash Flow | 0.00 | 6.35M | -6.02M | 0.00 | 0.00 |
| Financing Cash Flow | 18.56M | 2.90M | 20.47M | 2.25M | 2.05M |
Intensity Therapeutics, Inc. Technical Analysis
Negative
5.88
Price Trends
7.70
Negative
9.25
Negative
8.44
Negative
Market Momentum
-0.53
Positive
37.98
Neutral
27.79
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INTS, the sentiment is Negative. The current price of 5.88 is below the 20-day moving average (MA) of 6.74, below the 50-day MA of 7.70, and below the 200-day MA of 8.44, indicating a bearish trend. The MACD of -0.53 indicates Positive momentum. The RSI at 37.98 is Neutral, neither overbought nor oversold. The STOCH value of 27.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INTS.
Intensity Therapeutics, Inc. Risk Analysis
Intensity Therapeutics, Inc. disclosed 61 risk factors in its most recent earnings report. Intensity Therapeutics, Inc. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Intensity Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $486.21K | -0.24 | ― | ― | 178.82% | -4121.10% | |
43 Neutral | $14.94M | -11.99 | -370.86% | ― | ― | 46.41% | |
41 Neutral | $1.40M | -148.02 | -63.03% | ― | -100.00% | 86.75% | |
| ― | $2.43M | -0.17 | -168.95% | ― | ― | 90.27% |
* Healthcare Sector Average
INTS
Intensity Therapeutics, Inc.
5.88
-44.12
-88.24%
BDRX
Biodexa Pharmaceuticals
0.62
-14.78
-95.99%
QCLS
Q/C Technologies
3.45
-36.95
-91.46%
SCNI
Scinai Immunotherapeutics
0.57
-2.28
-80.00%
OGEN
Oragenics
0.56
-5.44
-90.66%
Intensity Therapeutics, Inc. Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Intensity Therapeutics Expands ATM Equity Offering Capacity
Neutral
Mar 23, 2026
On March 23, 2026, Intensity Therapeutics, Inc. increased the capacity of its existing at-the-market equity offering program to $60 million, expanding the amount of common stock it may issue under an agreement with H.C. Wainwright Co. LLC. The co...
Delistings and Listing ChangesRegulatory Filings and Compliance
Intensity Therapeutics Regains Nasdaq Compliance, Stabilizing Market Listing
Positive
Mar 6, 2026
On March 5, 2026, Intensity Therapeutics, Inc. received formal notice from Nasdaq that it had regained compliance with the exchange’s minimum bid price rule after its shares closed at or above $1.00 for 10 consecutive trading days from Febru...
Regulatory Filings and ComplianceStock Split
Intensity Therapeutics Announces 1-for-25 Reverse Stock Split
Negative
Feb 13, 2026
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company specializing in intratumoral cancer therapies built on its proprietary DfuseRx technology, is advancing its lead candidate INT230-6 through Phase 2 and Phase 3 trials in sof...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.